HIGH RISK NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA
Clinical trials for HIGH RISK NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH RISK NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for HIGH RISK NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo aims to train immune system to fight bladder cancer
Disease control Recruiting nowThis early-stage trial is testing a new peptide vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab (Keytruda) in 30 adults with high-risk non-muscle invasive bladder cancer that did not respond to or could not tolerate standard BCG therapy. The vaccine is de…
Matched conditions: HIGH RISK NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a single, smarter surgery spare bladder cancer patients a second operation?
Disease control Recruiting nowThis study compares two approaches for treating non-muscle invasive bladder cancer. The standard approach uses two surgeries: one to remove the tumor and a second to check for leftover cancer. The new approach uses a single, enhanced surgery with a special dye and light to better…
Matched conditions: HIGH RISK NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA
Phase: PHASE4 • Sponsor: University of Roma La Sapienza • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC